CBC Merges Two Shanghai Companies, AffaMed and EverInsight, into One
October 14, 2020 at 06:12 AM EDT
CBC Group (formerly C-Bridge Capital), a Singapore-Shanghai investor, merged two of its Shanghai portfolio companies, AffaMed Therapeutics and EverInsight Therapeutics, into a single entity under the AffaMed name. Both companies in-license ophthalmologic and central nervous system (CNS) products. In 2019, AffaMed acquired China rights to three Samsung Bioepis ophthalmology biosimilars. In June, EverInsight acquired China/Southeast Asia rights to a rapid-onset anxiety treatment from VistaGen in a $177 million agreement. More details.... Share this with colleagues: // //